Conjugate Group

The Deloitte 2025 Life Sciences Outlook echoes the trends and sentiments we've been discussing with clients. There is a nearly universal (if cautious) sense of optimism for the year ahead. From the normalization of the IPO and investment landscape to breakthroughs in technology, these conversations reveal exciting opportunities for innovation and growth. With the rebuilding phase of 2024 behind us, the industry is poised for a more robust 2025! Key Highlights from the Report: **Optimism in the Industry:** 75% of global life sciences executives, including those from biopharma and pharmaceutical companies, express optimism about 2025. Among them, 68% anticipate revenue growth, and 57% foresee margin expansions driven by technological advancements and evolving consumer expectations. **AI-Driven Digital Transformation:** Generative AI and cloud computing are revolutionizing product development and operations in biopharma and pharmaceuticals. Approximately 60% of pharmaceutical executives recognize AI as essential for advancing drug discovery, accelerating clinical trials, and streamlining supply chains. **Oncology, Rare Disease, and the GLP-1 Landscape:** The prominence of GLP-1 drugs in 2024 reflects the sector’s growth, extending applications beyond Obesity and Diabetes into areas like Sleep Apnea and NASH/MASH. Oncology and Rare Disease continue to attract significant investments, bolstered by favorable regulations and a growing emphasis on personalized medicine. Innovations in biomarkers and genomics, amplified by AI, are driving these advancements to improve patient outcomes. **Strategic Partnerships:** Forming alliances and strategic partnerships remains critical for strengthening pipelines and building resilience against market uncertainties. At Conjugate Group, we have noted these trends through our conversations with clients, and have aligned our strategies accordingly. Our expertise in Flexible Drug Development drives operational efficiency across the clinical development life cycle. Whether providing individual resources, outsourced functions, or in-sourced multi-functional teams, we enable companies to navigate the complexities of drug development with confidence, even in an unpredictable industry. #FlexibleDrugDevelopment #ConjugateGroup #Biopharma

In the field of recruitment, there is a common trend of discontent among individuals regarding the recruiting process generally and recruiters specifically. However, amidst this backdrop, I would like to highlight a positive experience. For those navigating the job market in the biotech/pharma sectors, my interactions with Conjugate Group stand out as exceptional over the last ten years. CEO Andrew J. Young and recruiter David Pratt have set a high standard of professionalism, expertise, reliability, and trustworthiness. David's communication approach is characterized by openness, friendliness, and transparency, emphasizing the significance of strong recruiter-client relationships. At Conjugate Group, the policy strictly prohibits ghosting, ensuring a respectful and responsive recruitment experience. For anyone seeking a new opportunity, you would do well to contact David Pratt at Conjugate Group!

Interesting story. We are seeing an increase in our clients asking for more face time. Not necessarily with our consultants but with our client decision makers. Though, at times our clients are asking for monthly face-to-face meetings with our consultants, dependent upon project/skill-set. We will see...

I have been working with growing/emerging biopharma groups for over 25 years in the Boston/Cambridge area. At Conjugate Group, we speak with hundreds of industry leaders and professionals each week and see a larger picture, even trends/counter trends. With the reality of 2023 staring Conjugate in the face a year ago, I decided to use it as a growth year, building capability and staff to meet the returning demand of 2024/2025. As we get into the 3rd Quarter of 2024 its important to know what we are experiencing. We've realized strong growth using 1st Quarter of 2023 as a baseline. There are more requests for our clinical development and operations people, for example. This is good for that subset of professionals that were the most affected by the downturn in late 2022/2023. And remember: stability is not getting a job at any one firm be it Pfizer or Novartis, etc. Rather, I have always thought of stability being the sum of your skills, attitude and network. Network, perhaps, being the most key thing in the equation. If these 3 things are alive and growing, you will weather the storms of biotech every time. We are excited for 2025!